CRISPR Therapeutics AG 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromto.Commission File Number: 001-37923 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Not Applicable(I.R.S. EmployerIdentification No.) Switzerland(State or other jurisdiction ofincorporation or organization) Baarerstrasse 146300 Zug, Switzerland(Address of principal executive offices) +41 (0)41 561 32 77(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.YES☒NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large Accelerated filer☒Non-accelerated filer☐ Accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of April 30, 2026, there were 96,448,792 shares of registrant’s common shares outstanding. Throughout this Quarterly Report on Form 10-Q, the “Company,” “CRISPR,” “CRISPR Therapeutics,” “we,” “us,” and“our,” except where the context requires otherwise, refer to CRISPR Therapeutics AG and its consolidated subsidiaries; “ourboard of directors” refers to the board of directors of CRISPR Therapeutics AG; and we generally refer to CASGEVY®(exagamglogene autotemcel [exa-cel]), as “CASGEVY”. “CRISPR Therapeutics®” standard character mark and design logo, “CRISPRX™,” “CRISPR TX™,” “CTX213™,”“CTX310®,” “CTX321™,” “CTX340™,” “CTX460™,” “CTX611™”and “SyNTase™”are trademarks and registeredtrademarks of CRISPR Therapeutics AG. CASGEVY®and the CASGEVY logo are registered trademarks of Vertex PharmaceuticalsIncorporated, and Vertex Pharmaceuticals Incorporated is the manufacturer and exclusive license holder of CASGEVY. All othertrademarks and registered trademarks contained in this Quarterly Report on Form 10-Q are the property of their respectiveowners. Solely for convenience, trademarks, service marks and trade names referred to in this Quarterly Report on Form 10-Q mayappear without the ® or ™ symbols and any such omission is not intended to indicate waiver of any such rights. FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve substantial risks and uncertainties.All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q are forward-lookingstatements. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,”“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “potential,” “will,” “would” or the negative or plural of thesewords or similar expressions or variations, although not all forward-looking statements contain these identifying words. Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements about: •our strategic plans to develop and, if approved, subsequently commercialize any product candidates we may develop,including plans and expectations for the commercialization of, and anticipated benefits of, CASGEVY, including plansfor patient access to CASGEVY;•the safety, efficacy and clinical progress of various clinical programs, including those for CASGEVY, zugocabtagenegeleucel, CTX310 and CTX611;•the status of clinical trials, including development timelines and discussions with regulatory authorities related toproduct candidates under development by us and us and our collaborators;•the results of preclinical studies and clinical trials, including ongoing clinical trials and any planned clinical trials, an